SAN DIEGO, Jan. 10, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between November 2, 2023 and October 30, 2024, inclusive (the "Class Period"), have until March 10, 2025 to seek appointment as lead plaintiff of the Regeneron class action lawsuit. Captioned Radtke v. Regeneron Pharmaceuticals, Inc., No. 25-cv-00145 (S.D.N.Y.), the Regeneron class action lawsuit charges Regeneron and ce ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Regeneron (REGN) . This company, which is in the Zacks Medical - Biomedical and Genetics industry, shows potential for another earnings beat.This biopharmaceutical company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters wa ...

LOS ANGELES, Jan. 10, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ: REGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 2, 2023 and October 30, 2024, inclusive (the ...

NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acqu ...

SAN FRANCISCO, Jan. 9, 2025 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after shares of the company plunged $84.59 on Oct. 31, 2024, wiping out about $9 billion of market value.Hagens Berman has opened an investigation into whether Regeneron may have misled investors about its marketing and reimbursement practices related to its EYLEA® product, an injection to treat age-related macular degeneration by inhibiting anti vascular endothelial growth factor ...

NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) securities between November 2, 2023 and October 30, 2024, inclusive (the “Class Period”). The lawsuit seeks to recover damages for the Company’s investor ...

TARRYTOWN, N.Y., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2024 financial and operating results on Tuesday, February 4, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the ’Investors and Media’ page of Regeneron’s ...

I’m a stock analyst with an MBA and a background in healthcare, bringing years of experience as a Registered Nurse dedicated to patient care. I've had the privilege of sharing my insights on Seeking Alpha since 2017. I am most interested in identifying underlying assumptions in stock valuations by emphasizing financial modeling techniques like DCF analysis. I then provide scenario-based forecasts to help readers gauge reasonable outcomes. I am influenced by books like Superforecasting and Antifragile. As su ...

Investigational REGN7508 (catalytic domain) and REGN9933 (A2 domain) are being evaluated for their potential to control thrombosis while minimizing bleeding risk in a variety of patient populations and clinical settings Evaluated against current standards of care, single doses of REGN7508 and REGN9933 administered 12 to 24 hours after total knee replacement demonstrated robust antithrombotic effects Phase 3 program to be initiated in 2025 TARRYTOWN, N.Y., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmac ...

公司研究 - Regeneron Pharmaceuticals宣布其Eylea HD在治疗视网膜静脉阻塞（RVO）引起的黄斑水肿的晚期研究中达到了主要终点[1] - Eylea HD是Eylea的高剂量版本，Eylea已获批用于治疗湿性年龄相关性黄斑变性、糖尿病性黄斑水肿、糖尿病性视网膜病变和RVO[2] - 在QUASAR III期研究中，Eylea HD每八周注射一次（初始三到五次每月注射）在36周时与每月注射的Eylea相比，在最佳矫正视力改善方面达到了非劣效性[3] - 约90%的Eylea HD患者在36周治疗期间能够维持八周的注射间隔[6] - Eylea HD的安全性与Eylea相当，并与之前关键研究中观察到的Eylea HD安全性一致[6] - 公司计划在2025年第一季度向全球监管机构提交QUASAR III期研究结果，寻求Eylea HD治疗RVO的标签扩展[7] - Eylea由Regeneron与拜耳共同开发，Regeneron负责美国市场的净销售额，拜耳负责美国以外市场的净销售额，Regeneron记录其在美国以外销售中的利润/亏损份额[8] 行业研究 - 目前所有FDA批准用于RVO适应症的抗VEGF疗法都需要每月注射，这对许多患者来说是一个负担[5] - Eylea HD的QUASAR研究结果表明，该药物可以在减少注射次数的情况下改善RVO患者的视力，这标志着治疗的重大进步，提高了患者的生活质量和潜在的依从性[5] 市场表现 - 过去三个月，Regeneron的股价下跌了35.7%，而行业平均下跌了10.8%[4] - 过去三个月，Castle Biosciences的股价下跌了7.8%[10] - 过去三个月，Spero Therapeutics的股价下跌了23.6%[11] 其他公司 - Castle Biosciences在过去的60天里，2024年每股收益预估从亏损59美分改善为盈利34美分，2025年每股亏损预估从2.15美元收窄至1.84美元[10] - Spero Therapeutics在过去的60天里，2024年每股亏损预估从1.59美元收窄至1.29美元，2025年每股亏损预估从1.54美元收窄至79美分[11] - Castle Biosciences在过去四个季度中每个季度的盈利都超过了预期，平均超出预期172.72%[11] - Spero Therapeutics在过去四个季度中有两个季度的盈利超过了预期，平均超出预期94.42%[12]